![]() The company will list on the Nasdaq under the symbol "LDOC", it said.Īlibaba Health is the healthcare flagship platform for the Alibaba Group Holding Ltd (9988.HK), conglomerate. LinkDoc said it will use the proceeds from the offering to strengthen its research and development capacities and for investments and acquisitions, among others. introducing measures that could result in foreign companies being delisted from American stock exchanges within three years if they do not comply with the country's auditing standards. The company's listing plans come despite the U.S. ![]() The Beijing-based company, which offers cancer-focused healthcare services, reported a 41% jump in revenue for the three months ended March 31, according to the filing.įor the same period, net loss attributable to LinkDoc widened to 135.4 million renminbi ($21.17 million) from 61.6 million renminbi a year earlier. However, the importance of patient selection and management process, as well as accurate lymph node staging must be acknowledged when making the surgical decision (clinical registration number: NCT03429673).Ĭlinical stage I non-small cell lung cancer (clinical stage I NSCLC) complications lobectomy perioperative outcomes sublobar resection.June 14 (Reuters) - LinkDoc Technology Ltd, a medical data company backed by a subsidiary of Alibaba Health Information Technology Ltd (0241.HK), filed for an initial public offering in the United States on Monday. Sublobar resection was associated with significantly better perioperative outcomes without compromising short term survival in elderly patients with clinical stage I NSCLC. Sublobar resection was more frequently performed in patients who were elder, had more comorbidities and smaller, left-sided adenocarcinoma (P75 years, at pathologic stage I, and those who smoking or undergoing video-assisted thoracoscopic surgery (VATS) or segmentectomy and lobectomy. Subgroup analysis was further carried out to explore the potential sources of heterogeneity.Īmong the 1,579 eligible patients, 1,164 (73.7%) underwent lobectomy and 415 (26.3%) underwent sublobar resection (106 segmentectomy and 309 wedge resection). Perioperative outcomes and overall survival were analyzed by using propensity score matching to adjust for selection bias. Clinical data on demographic and tumor characteristics, surgical details were collected. ![]() Clinical stage I NSCLC patients who underwent lobar or sublobar resection (segmentectomy and wedge resection) at the Department of Thoracic Surgery of 10 tertiary hospitals between January 2014 and September 2017 were retrospectively reviewed from the national collaborative prospective lung cancer database (LinkDoc Technology Co, Ltd., Beijing, China). This is a multicenter retrospective cohort study. lobectomy for management of elderly patients (≥65 years) with clinical stage I NSCLC. The present study aimed to comparatively study the perioperative outcomes and overall survival of sublobar resection vs. However, controversy remains as to whether it is adequate for elderly patients. Sublobar resection has emerged as an alternative to lobectomy for management of early-stage non-small cell lung cancer (NSCLC). ![]() 12 Medical Affairs, LinkDoc Technology Co, Ltd., Beijing 100080, China.11 Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.10 Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300051, China.9 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou 450008, China.8 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing 210009, China.7 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing 210009, China. ![]()
0 Comments
Leave a Reply. |